New study aims to tame dangerous immune reaction in myeloma therapy

This study tests whether giving a single dose of tocilizumab before the cancer drug ramantamig can prevent or reduce cytokine release syndrome (CRS), a serious flu-like reaction, in people with relapsed or refractory multiple myeloma. About 230 participants will receive either tocilizumab or a placebo, and researchers will track how many avoid severe CRS within 28 days. The goal is to make treatment safer and more tolerable for patients whose cancer has returned or not responded to prior therapy.